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In the 25 years since the ﬁrst TIPS intervention has been per-
formed, technical standards, indications, and contraindications
have been set up. The previous considerable problem of shunt
failure by thrombosis or intimal proliferation in the stent or in
the draining hepatic vein has been reduced considerably by the
availability of polytetraﬂuoroethylene (PTFE)–covered stents
resulting in reduced rebleeding and improved survival. Unfortu-
nately, most clinical studies have been performed prior to the
release of the covered stent and, therefore, do not represent the
present state of the art. In spite of this, TIPS has gained increasing
acceptance in the treatment of the various complications of por-
tal hypertension and vascular diseases of the liver.
 2013 European Association for the Study of the Liver. Published
by Elsevier B.V. Open access under CC BY-NC-ND license.Introduction and history of TIPS
In 1969 already, Joseph Rösch et al. ﬁrst described an interven-
tional technique to establish a transjugular intrahepatic portosys-
temic shunt in dogs by implanting a silicone-coated spring coil to
achieve patency for as long as 2 weeks [1,2]. These early experi-
ments were continued by creation of a TIPS in cirrhotic livers
and in cadavers [3]. In the late ‘70s, Burgener and Gutierrez [4]
constructed shunt tracts in dogs with portal hypertension by bal-
loon dilatation of the parenchymal track that normalized the ele-
vated portal pressure, but occluded within 1 week. In 1982,
Colapinto and Gordon were the ﬁrst to apply this technique clin-
ically in more than 20 patients [5,6]. The long-term results were,
however, not encouraging and most patients rebled and 9 died
within a month.
With the introduction of expandable metallic stents in the
mid-1980s by Palmaz, high long-term patency rates were
achieved by implanting such stents in cirrhotic livers of dogs
[7,8]. Based on own experiences in hepatic vein catheterization
and transjugular liver biopsies, the Freiburg TIPS project was
started in 1987 after its approval by the local ethics committee.Journal of Hepatology 20
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implantation of a metallic Palmaz-stent was performed in Frei-
burg in 1988 and 9 more procedures followed in the same year
[9–13]. Of the 10 patients who were intended to treat, TIPS could
be implanted successfully in 7. Two of these 7 patients died early.
Interventions lasted an average of 8 hours and consisted of a
transjugular as well as a percutaneous transcostal approach to
place a metallic target (Dormia bascet) in the right branch of
the portal vein. Due to complications and technical difﬁculties
in establishing the TIPS, the project was discontinued until spring
1990 when Jean Marc Perarnau from Metz, France, joined our
group. With his improved puncture technique including sono-
graphic targeting of the portal vein, we were able to perform
the procedure in its present form within 1 to 2 hours with a con-
siderably reduced complication rate [14]. This was the start of a
series of about 50 patients treated within 1990 and 500 patients
treated until 1995 in Freiburg. A summary of the early results of
the 2 leading centers at this time, Freiburg and San Francisco, was
published in 1993 [15].
The last decade of the millennium was devoted to technical
problems solving and to performing numerous randomized
clinical studies [16]. Finally, patients’ selection and the deﬁni-
tion of the best indications have been worked out and discussed
in consensus conferences [17,18]. Steady adaptation of this
process is necessary to include new results obtained with
increasing experience and new technical facilities such as
covered stents.
The present review concentrates on speciﬁc technical aspects
and clinical implications based on former and actual study results.
Technical considerations
Pre-interventional measures
Before TIPS implantation, hepatic functional insufﬁciency and
clinically overt hepatic encephalopathy should be excluded. A
duplex examination should exclude portal and hepatic arterial
abnormalities. Road mapping by CT or MRI is not routinely nec-
essary but may help facilitate the anatomical orientation. In
patients with suspected or known cardiac disease, an echocardi-
ography should be performed to exclude signiﬁcant diastolic or
systolic cardiac failure. In patients with refractory ascites or
hydrothorax, paracentesis and/or thoracentesis should be per-
formed. This may reposition the liver from a more transversal
into a more frontal posture, facilitating the portal puncture. It
also improves the quality of the ﬂuoroscopic picture and reduces13 vol. 59 j 1081–1093
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the radiogenic exposure of the patient and physician. In addition,
the respiratory function improves and facilitates sedation.
Intervention
The technical performance of the TIPS procedure may be some-
what different in the US and Europe where not only Radiologists
but also Gastroenterologists have given their input. Thus, many
centers in Europe use sedation with midazolam, piritamide, and
propofol while in the US general anesthesia with endotracheal
intubation is preferred [19]. In addition, sonographic targeting
is commonly performed by Gastroenterologists while Radiolo-
gists often trust preinterventional imaging [17]. For the creation
of the TIPS procedure, two puncture sets are presently in use:
the modiﬁed open Colapinto or Ross needle with an adapted mul-
tipurpose catheter and a closed coaxial system where a stylette is
advanced through a canula. The open needle is relatively inex-
pensive and allows rapid execution of the puncture. With its
use, complete TIPS procedures have been performed in less than
20 min. The closed coaxial needle set is more expensive, more
complex, and time consuming, but may be less invasive. Studies
comparing the two equipments have not been performed so far.
After an appropriate branch of the intrahepatic portal vein has
been punctured, a guidewire followed by a pigtail catheter is
introduced into the splenic vein and portal venography and pres-
sure measurements are performed. If present and indicated, col-
laterals are now occluded using bucrylate, coils or Amplatzer
plug. The parenchymal track is then dilated and a stent is placed.
To avoid shunt related complications, stents with a nominal
diameter of 10 mm should be employed but dilated only to
8 mm. This may result in a more limited pressure reduction,
not always achieving the recommended threshold of 12 mmHg
[19–22], but possibly reducing the rate of TIPS-induced hepatic
encephalopathy [22,23]. In case of insufﬁcient response, further
pressure reduction can be achieved by a second intervention.
However, no studies are available showing that the presently pre-
ferred self-expandable stents with a nominal diameter of 10 mm
keep the reduced diameter over time. This certainly depends on
the radial forces of the stent and compliance of the cirrhotic liver,
both may differ to a great extent. Stents with low radial forces
(e.g., Viatorr) may be preferred.
A ﬁnal portography and pressure measurement in the main
portal vein and the right atrium are performed. In contrast to
the measurements of the pressure gradients performed and pub-
lished in studies investigating the effect of drugs, the free hepatic
vein pressure measurement is usually replaced by the measure-
ment in the right atrium. Measurement in the hepatic vein after
TIPS is compromised by the stent and the high ﬂow in the hepatic
vein. Instead, measurement in the inferior caval vein at the level
of the hepatic veins has been suggested [24]. However, the loca-
tion of the tip of the catheter straight below the right atrium is
often difﬁcult and distinction between the upper part of the caval
vein and the right atrium is not always possible. Therefore, in the
setting of TIPS, most investigators measure the porto-atrial gradi-
ent which is slightly higher than the gradients obtained between
the portal vein and the hepatic or inferior caval veins.
Should anticoagulation or antibiotics be provided during or
after the TIPS procedure? This is an open question which has
often been discussed. The advantage of platelet aggregation
inhibitors has been demonstrated for bare stents [16,25]. Our
present approach is to treat patients with bare stents and with1082 Journal of Hepatology 2013higher platelet count (e.g., >100000/ll) with acetylic salicylic
acid (100 mg/day). Whether this strategy can also be recom-
mended for covered stents is not investigated so far. Their intro-
duction led to marked decrease in shunt dysfunction [15% vs.
44%], and a lower rate of clinical relapse [10% vs. 29%] [26,27].
However, it should be noticed that the advantage diminishes
with time to require shunt revision of about 50% after a 5-year
follow-up [28]. Post-interventional infection has been observed
in up to 20% of patients and prophylactic antibiosis with Ceftriax-
one [29], but not with Cefotiam [30], has been suggested. In addi-
tion, infection of the stent lumen, named ‘‘endotipsitis’’, has been
described with a calculated incidence of 1.3% [31,32]. It can be
assumed that, in the meanwhile, the incidence of post-interven-
tional infection decreased by better technical skills (fewer cathe-
ter exchanges), questioning the usefulness of prophylactic
antibiosis. However, complicated procedures requiring many
changes of catheters and sheaths may have a higher rate of infec-
tion, justifying prophylactic antibiotic treatment.
The early post-procedural setting consists of monitoring of the
blood pressure, haemoglobin/hematocrit and maybe urine vol-
ume during 24 hours. With few exceptions, intensive care is not
necessary. In general, in patients with variceal bleeding, ß-block-
ers are withdrawn and in patients with refractory ascites, diuretic
medication is reduced by half. A Duplex-sonographic examina-
tion is performed before patient’s discharge.
The ‘‘direct’’ TIPS
In patients with a Budd-Chiari syndrome, the catheterization of a
heptic vein may not be possible. In these as well as in the rare
patients with unaccessible hepatic veins, a direct puncture
through the inferior caval vein may be inevitable. A series of 40
patients with direct TIPS (DIPS) using intravascular ultrasound
has been reported showing a high success and patency rate
[33,34]. Another technique of a direct TIPS, which was applied
to 11 patients with Budd-Chiari syndrome, used a percutaneous
transabdominal approach to the left portal branch which was
then extended to the inferior caval vein [35].
Technical complications
Unfortunately, prospective studies investigating the technical
complications are not available. Perforation of the liver capsule
without or with intraperitoneal hemorrhage has been described
in 33 and 1–2% of the procedures, respectively [19]. However, in
centers using sonography during the puncture process, these
complications are almost abolished. The same is true for clinically
signiﬁcant hemobilia or hemolysis, complications which have
been seen more frequently at the beginning of the TIPS era [16].
With the use of modern stents, stent misplacement or migration
is also very rare. Frequencies of 20% proximal or distal displace-
ment given in a recent review [20] are, in our experience, unusual.
In particular, the Viatorr stent is designed to be placed with great
accuracy and misplacement is almost impossible (Fig. 1).
Long-term follow-up
Doppler ultrasound is the most valuable means to estimate shunt
function. The parameters which should be evaluated before and
after TIPS implantation are summarized in Table 1. In general,
the pre-procedural low-ﬂow velocity in the portal vein (Vmax:
10–20 cm/sec) increases by TIPS by a factor of 2–4 tovol. 59 j 1081–1093
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Fig. 1. TIPS with Viatorr-stent in its optimal position. The distal part (2 cm) of
the stent is uncovered (arrow heads). After its release, the stent is drawn back
until an increasing resistance signals its correct position. The ring (black arrow)
marks the beginning of the covering (asterisk). Before the procedure, an external
metallic marker has been placed sonographically to facilitate the puncture of the
right portal branch (white arrow).
JOURNAL OF HEPATOLOGY40–60 cm/sec [36–41]. A post-TIPS portal vein ﬂow velocity of
less than 30 cm/sec suggests shunt insufﬁciency. The ﬂow veloc-
ity in the stent is expected to be between 80 and 160 cm/sec
shortly after TIPS. Values below 60 or above 180 cm/sec indicate
shunt insufﬁciency. In particular, any value lower than 40 or
higher than 200 cm/sec clearly indicates shunt malfunction
[41]. It should be emphasized that measurements in the stent-
shunt or in the draining hepatic vein are only reliable in cases
of simple stenoses (Figs. 2 and 3). In cases with a complex struc-
ture of the intimal proliferation in the stent or in the draining
hepatic vein, the measurements are not reliable and normal val-
ues cannot exclude stenosis (Figs. 2 and 4). Therefore, in case of
normal values within the stent, the ﬁndings in the portal vein
deﬁne whether shunt function is sufﬁcient or not. In addition, a
change in ﬂow direction of the intrahepatic portal branches from
retrograde shortly after TIPS to prograde may also be a good qual-
itative indicator of shunt malfunction [37]. If simple stenosis is
seen, the Bernoulli equation (Dp = 4 v2) can be applied to calcu-
late the pressure gradient Dp (in mmHg) across the stenosis from
the ﬂow velocity measured in the stenosis (Vmax in m/sec).Table 1. Duplex-sonographic ﬁndings obtained from the literature [36–41] before an
are calculated according to ﬂow = p  d2/4 ½ Vmax.
Before TIPS
Portal vein
Flow velocity (V
Direction of intrahepatic flow
max, cm/sec) 15
Hepatopedal (90%)
Diameter (mm) 14
Flow (ml/min) 800
Stent
Flow velocity (Vmax, cm/sec)
Stent diameter (mm)
Flow (ml/min)
Hepatic vein
Flow velocity (Vmax, cm/sec)
Journal of Hepatology 2013Accordingly, a ﬂow velocity (Vmax) of 180 cm/sec (1.8 m/sec)
indicates a pressure gradient across the stenosis of 13 mmHg. It
could be demonstrated that calculated gradients using the Ber-
noulli equation closely correlate with gradients determined by
catheter measurement (r = 0.84) [41].
When TIPS dysfunction is suspected, revision is not generally
indicated in the absence of clinical symptoms. In patients with
previous variceal bleeding, the decision should be based on the
endoscopic veriﬁcation of signiﬁcant varices. Certainly, revision
should not be performed in patients who developed severe liver
failure or hepatic encephalopathy at the time of TIPS patency. If
the original TIPS was created using a bare-metal stent, a covered
stent should now be implanted [42].Major adverse events, limitations, and contraindications
Hepatic function
Due to the diversion of portal venous ﬂow, an increase in biliru-
bin concentration is frequent due to decreased liver perfusion
while albumin or INR is not affected [43–45]. A small study
including 15 patients investigated the effect of TIPS on aminopy-
rin breath test, monoethylglycinexylidide test (MEGX), bilirubin,
albumin, and PT-time. Compared to values obtained before TIPS,
no signiﬁcant changes were seen 1, 3, and 6 months after TIPS
[45]. Nevertheless, few patients develop severe liver failure char-
acterized by a rapid increase in bilirubin concentration. They
require immediate TIPS occlusion to prevent death. Fortunately,
the loss or reduction of the portal perfusion by TIPS induces an
immediate rise in the arterial blood ﬂow which is known as the
arterial buffer response [46]. This explains why TIPS-induced
hypoxic damage of the liver is a rare exception. Thus, endoluminal
ﬂow measurements showed an immediate increase in the arterial
liver perfusion from 599 ± 100 ml/min to 749 ± 161 ml/min when
the TIPS is opened [47].Hepatic encephalopathy (HE)
The incidence of HE after TIPS varies from 15% to 48% [48–55]. In
controlled trials comparing TIPS with medical treatment ford after TIPS and values indicating shunt failure. The portal vein and stent ﬂow
After TIPS
Patent shunt Shunt failure
40 <30
Hepatofugal (90%) Hepatopedal
14
1800 <1200
110 <50, >180
8
1600
>180
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Fig. 2. Schematic representation of the types of shunt stenosis. A simple
stenosis consists of a small web-like intimal proliferation with a high ﬂow
velocity (Vmax) usually exceeding 2 m/sec. Duplex sonography can accurately
detect the stenosis and the gradient across the stenosis can be estimated using
the Bernoulli-equation. By contrast, a complex stenosis consists of a lining of
neointima in the stent with variable thickness. Duplex-sonography does usually
not deliver reliable results and the Bernoulli-equation cannot be applied.
250 cm/s
40 cm/s
Fig. 3. Example of a simple stenosis in the draining hepatic vein exhibiting
Vmax of >2 m/sec.
Fig. 4. Example of a complex stenosis with lining of the stent. Duplex
sonography of the stent ﬂow velocity is not reliable and shunt function must be
assessed by portal ﬂow parameters.
Reviewvariceal bleeding, the incidence of HE was always greater in
patients who received a TIPS [56–58]. In patients with ascites, a
recent meta-analysis of individual patient data showed that the
cumulative probability of developing a ﬁrst episode of HE during
follow-up was not different between TIPS and paracentesis1084 Journal of Hepatology 2013groups (p = 0.36) [59]. However, patients allocated to TIPS had
signiﬁcantly more episodes of HE with regard to both total num-
ber of episodes (1.13 ± 1.93 vs. 0.63 ± 1.18, p = 0.006) and number
of severe episodes (0.68 ± 1.0 vs. 0.24 ± 0.50, p = 0.008). It should
be pointed out that most studies were not designed to investigate
HE [60]. Longitudinal cohort studies may be biased by comparing
a retrospective evaluation before TIPS (past history of HE
together with the assessment at index hospitalization) with a
prospective evaluation after TIPS. In addition, evaluation of HE
was performed by subjective measures (e.g., New Haven criteria)
and unblinded investigators, a fact which may have inﬂuenced
the result. The study by Kircheis et al. using the critical ﬂicker fre-
quency test [61] showed a stable HE-severity in the control group
(no TIPS) while patients with TIPS showed no change in HE-
severity in 44%, deterioration in 35%, and improvement in 21%
of the patients. Thus, while controls remained stable, TIPS had a
considerable potential to deteriorate HE but also a chance for
its improvement.
Prediction of HE is difﬁcult since many variables are involved.
Most often, increased age, advanced liver failure (expressed by
elevated bilirubin), a history of encephalopathy before TIPS inser-
tion, and low serum sodium concentration have been found to
predict HE [49–51,53]. In patients with an acute bleed, predictors
other than biometrical ones have limited value since the bleeding
may affect psycho-neurological performance.
While primary factors (liver function and blood ﬂow) inducing
HE are expected to be worsened by the shunt, the shunt may
improve some secondary factors such as the mean arterial pres-
sure, serum sodium concentration, renal function, and nutrition
[62,63]. In contrast to serial paracentesis, TIPS leads to a signiﬁ-
cant improvement of these parameters including total body
nitrogen and total body protein [64–66], muscle mass, and albu-
min concentration [67].
For prevention of HE, attempts have been made to limit
shunting by reducing the diameter of the shunt. As demonstrated
recently, 25 out of 27 patients who developed HE after TIPS
implantation had a pressure gradient of <12 mmHg [22]. Thus,
in patients with a higher risk of HE (and/or poor liver function),
the portosystemic pressure gradient should be decreased with
great caution by implantation of small stents. Surprisingly, a
study comparing 8 vs. 10 mm diameter covered-stent TIPS could
not show a difference in HE between groups although the pres-
sure gradient was higher in the 8 than in the 10 mm group (8.9
vs. 6.5 mmHg) [68]. The study was discontinued preterm because
of unsatisfactory efﬁciency of the 8 mm TIPS and did, therefore,
not reach a sample size necessary to assess differences in HE. Pre-
vention with drugs was studied recently showing no effect of
lactitol or rifaximin vs. no treatment [69].
Treatment of HE is medical including ornithin-aspartate,
branched chain amino acids, lactulose, and xifaxan [70]. In
patients receiving diuretics, exsiccosis is frequent and should be
ruled out. In refractory cases, shunt reduction by placement of
an hourglass-shaped ePTFE covered reducing stent led to an
immediate increase in the pressure gradient and to long-term
improvement of HE in all patients [71]. A more sophisticated
and variable approach has been reported recently [72]. Two
stents were released within the original stent-shunt. One of the
stents is a covered stent which remains patent. The other stent
is bare and short and placed besides the covered stent. The ﬁnal
ﬂow volume through the covered stent can be adjusted by expan-
sion of the bare stent. In view of the encouraging results with thevol. 59 j 1081–1093
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Fig. 5. Results of two randomized controlled trials [86,87] and one retro-
spective trial [88] comparing early TIPS with endoscopic and drug treatment.
Monescillo [86] selected and randomized patients with a pressure gradient of
P20 mmHg. Patients with a gradient <20 mmHg received medical treatment
only. Their survival rate is also given for comparison. The studies by Garcia-Pagan
[87,88] selected patients with Child-Pugh class B and active bleeding at index
endoscopy and class C patients (score 10–12).
JOURNAL OF HEPATOLOGYhourglass-stent and a potential risk of stent migration, the need
and advantage of this latter procedure seem to be questionable.
Limitations and contraindications
Older age, pre-TIPS HE and bilirubin >3 mg/dl are the most signif-
icant predictors of outcome and may be used as relative contra-
indications [16,43,73–76]. In addition, a number of scores
predicting outcome after TIPS have been investigated [77–81].
Thereby, the MELD score [77] including bilirubin, creatinine
and INR, was found to be superior to the Child-Pugh score at pre-
dicting post-TIPS mortality [78,80], or the Emory score [79]. A
MELD score above 18 predicts a signiﬁcantly higher mortality
3 months after TIPS, compared with patients with MELD scores
of 18 or less [79–81]. However, as shown in patients with refrac-
tory ascites, a strong correlation between mortality and MELD-
score was also found in paracentesis patients [59]. In patients
with MELD scores between 10 and 20, the estimated mortality
was always better in the TIPS than paracentesis groups [59].
Therefore, the MELD score cannot reliably guide the decision
for or against TIPS treatment in patients with refractory ascites.
Cardiac disease and moderate to severe pulmonary hyperten-
sion are also regarded as contraindications for TIPS. Recently, the
E/A ratio, an indicator for diastolic dysfunction, has been found to
predict survival after TIPS [82]. A pre-TIPS reduced E/A ratio was
correlated with reduced ascites clearance after TIPS (HR 7.3,
p <0.021) and increased post-TIPS mortality (HR 4.7,
p <0.035)[83]. The presence of diastolic dysfunction (E/A ratio
<1) 28 days after TIPS was associated with poor survival (RR
8.9, p <0.005) [84]. Thus, cardiac failure contributes to mortality
after TIPS implantation and, therefore, the determination of the
E/A ratio before and after TIPS insertion may be recommended
to better adjust its indication and post-TIPS surveillance. In this
context, the pro-brain natriuretic peptide (proBNP) and BNP con-Journal of Hepatology 2013centrations may also be of diagnostic value [85], but are not suf-
ﬁciently assessed as predictors of response and mortality in TIPS
patients so far.
Irrespective of the predictors used, they are not suitable to
decide pro or contra TIPS or continuation of the standard treat-
ment. They can only be used to advise the patient about the
expected outcomes and to decide on the urgency for liver trans-
plantation. In any case, adverse events and contraindications are
rarely absolute and they need always to be balanced against the
urgency of treatment escalation.
Key Points 1
• Improvement of skills and stents reduced complications
and improved patency
• Hepatic encephalopathy is still the major problem of
TIPS. To further reduce its incidence, small shunts
(8 mm) using covered stents with a nominal diameter of
10 mm are recommended and further dilatation should
be delayed until needed. More studies are needed to
further support this recommendation
• TIPS has gained an advanced position in the treatment
of patients with acute variceal bleeding with high risk
of early rebleeding. Variceal embolization together with
TIPS implantation may be recommended in patients
bleeding with low pressure gradients, but additional
studies are necessary
• The role of covered-stent TIPS in the secondary 
prophylaxis of variceal bleeding needs to be 
investigated. Until then, TIPS is a second line treatment
after medical treatment failed
Indications for TIPSTIPS has been used to treat most of the complications of portal
hypertension. Randomized controlled trials are available for var-
iceal bleeding and refractory ascites, whereas other indications
have been evaluated in uncontrolled studies only.
Bleeding indications
Acute esophageal variceal bleeding
Two recent randomized studies and one retrospective surveil-
lance study compared TIPS with medical treatment for acute
bleeding (Fig. 5) [86–88]. The ﬁrst study by Monescillo et al.
[86] included high risk patients with a pressure gradient above
20 mmHg measured within 24 hours after admission to receive
an early bare-stent TIPS (n = 26) or medical treatment (n = 26).
Compared with the medical group, the TIPS group had a signiﬁ-
cantly better outcome with respect to treatment failure, transfu-
sions, need for intensive care, and in-hospital and 1-year
mortality. In spite of the clear result of this study and possibly
due to lack of respective facilities, consensus statements were
not adapted and everyday clinical practice was not inﬂuenced.
The second study by García-Pagán et al. [87] used a more clin-
ical approach for patients’ selection. High-risk patients with
Child-Pugh class B and acute variceal bleeding at index endos-
copy or class C were randomized within 72 h after admission tovol. 59 j 1081–1093 1085
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receive a covered stent TIPS or medical treatment using ß-blocker
plus nitrate or endoscopic band ligation if unresponsive to drugs.
The early TIPS group had a signiﬁcantly lower rebleeding rate
(3% vs. 45%) and better survival (1-year: 87.5% vs. 61.3%)
(Fig. 5). Surprisingly, the incidence of HE was lower in the TIPS
group possibly due to the lower rate of rebleedings. The results
of the study were conﬁrmed by a post-RCT surveillance study
[88] (Fig. 5). In addition, a recent economic modelling of early
TIPS in high risk patients with acute variceal bleeding showed
cost effectiveness of the TIPS procedure compared to standard
therapy [89]. Consequently, the Baveno V conference in 2010 rec-
ommended considering early TIPS (within 72 h) in patients with
high risk of treatment failure [90].
Prophylaxis of rebleeding
Most randomized studies comparing TIPS with medical treat-
ment for prevention of rebleeding were performed in the 1990s
using bare metal stents. A total of 13 RCTs including 948 patients
were published and analysed. Rebleeding was reduced after
insertion of TIPS (9–40.6%) compared to medical therapy (20.5–
60.6%) [56–58]. However, there was a more than twofold increase
in the rate of development of hepatic encephalopathy after a TIPS
procedure. Mortality was comparable between the TIPS and
endoscopic/medical therapy groups. Since HE was considered to
have a greater negative impact than rebleeding on quality of life,
medical treatment was regarded as ﬁrst line treatment in the pre-
vention of variceal rebleeding [18,90]. It should be emphasised
that, at this time, bare stents were used exclusively and dilated
to up to 12 mm.
Variceal embolization
A prospective study found that embolization together with TIPS
implantation signiﬁcantly reduced rebleeding during a 4-year fol-
low-up (29% vs. 47%) although patients receiving additional
embolization had higher post-TIPS pressure gradients [91]. A con-
trolled study conﬁrmed these ﬁndings with 1-year rebleeding
rates of 19.5% in the TIPS plus embolization group compared to
41.5% in the TIPS group [92]. Both studies show unusually high
rebleeding rates questioning their quality with respect to the
shunt as well as the follow-up. Thus, additional studies are nec-
essary before variceal embolization can be recommended as a
valuable adjunct to TIPS treatment. To avoid reﬂux of bucrylate
into the portal vein, embolization with bucrylate should be per-
formed prior to implantation of the stent. After embolization,
the patient may exhibit upper abdominal pain probably due to
phlebitis.
Gastric variceal bleeding
Bleeding from gastric varices often occurs with a low portal pres-
sure gradient [93]. In these patients, the rationale for a decom-
pression alone may not be given and TIPS alone without
embolization may not be the optimal solution. This is conﬁrmed
by the ﬁnding that TIPS improved mortality only in patients with
pre-TIPS pressure gradients above 12 mmHg [93]. Nevertheless,
TIPS was superior to endoscopic embolization as demonstrated
in a controlled study [94].
Rare bleeding indications
Rare bleeding sites are ectopic varices, portal hypertensive gas-
tropathy, stomas or conduits or hemorrhoidal bleeding. Local
treatments are often impossible and inefﬁcient. Therefore, the1086 Journal of Hepatology 2013transjugular approach can be used to embolize the feeding vessel
and to implant a small diameter TIPS to facilitate reintervention
in case of rebleeding [95,96]. The use of TIPS for bleeding from
portal hypertensive gastropathy is not proven but case reports
suggest that TIPS may control bleeding in these patients [97]. In
contrast, chronic bleeding from gastric antral vascular ectasia
(GAVE) could not be successfully managed by TIPS [98].
Ascites and related complications
The treatment of refractory or recidivant and tense ascites and its
associated complications has changed considerably during recent
years. Large volume paracentesis (LVP) has been shown to be
safe, easy to perform, and has the advantages of immediate relief
of complaints and reduced duration of hospitalization [99]. It has,
however, a negative effect on systemic hemodynamics and renal
function [100] which often limits its use as a long-term treat-
ment. In contrast, TIPS offers a treatment option which even
improves renal function and systemic hemodynamics as well.
As summarized in a recent review [73], within 4 weeks after TIPS,
urinary sodium excretion and serum creatinine improve signiﬁ-
cantly and can normalize within 6–12 months. This is associated
with an increase in serum sodium concentration, urinary volume,
and glomerular ﬁltration rate together with a normalization of
plasma renin activity, aldosterone, and noradrenaline concentra-
tions during 4–6 months of follow-up (Fig. 6). In addition, 6 stud-
ies showed normalization of renal hemodynamics during a
12-month follow-up after TIPS [101–106]. These ﬁndings
strongly suggest that TIPS reverses the hyperdynamic circulation
and ameliorates central underﬁlling. Most likely, this is due to
redistribution of local resistances allowing the renal resistance
to decrease.
The effect of TIPS on redistribution of local resistances is
shown in Table 2. The values for total, splanchnic, hepatic/portal,
and renal resistances are calculated from variables (pressure gra-
dients DP, and ﬂow volumes F) obtained from the literature
[101,106–111]. The splanchnic and hepatic/portal resistances
have a serial arrangement while peripheral, renal, and splanch-
nic/hepatic resistancies are arranged in parallel. The inverse value
(1/R) (Table 3) represents the conductance (C = F/DP) which is, in
contrast to the resistance, additive in parallel. As shown in Fig. 7,
TIPS has a great inﬂuence on local conductancies. The total vascu-
lar conductance markedly increases (i.e., decreasing resistance),
shortly after opening of the TIPS, due to an almost unrestricted
ﬂow through the splanchnic bed. With time, the splanchnic/
hepatic conductance decreases (increasing resistance) but
remains above the pre-TIPS level. The peripheral conductance
decreases allowing the renal conductance to increase. Thus, cir-
culatory dysfunction gradually resolves by portal decompression
as it arose by portal hypertension.Efﬁcacy
A recent analysis of the literature on TIPS for refractory ascites
including 16 studies showed a complete response in 51% and a
complete and partial response not requiring paracenteses in
68% of the patients [112]. Analysing the individual data of 4 ran-
domized studies [43,113–115], the mean response to TIPS was
76% [59]. Recurrence of tense ascites occurred in 42% of patients
allocated to TIPS and 89% of patients allocated to paracentesis
(p <0.0001). Recurrence is mostly due to shunt insufﬁciency and
can be effectively treated by TIPS revision. Accordingly, thevol. 59 j 1081–1093
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Fig. 6. Summary of published data of plasma renin activity, aldosterone, and noradrenaline concentrations before and after TIPS implantation. Values normalized
within 1 year demonstrating improvement of systemic hemodynamics.
Table 2. Pressure gradients (DP), ﬂows (F) and resistances (R) calculated according to R = DP/F (mmHg/L min1). Values obtained are transformed into
dyne  s  cm5 by multiplying with 80. DP and F of the respective vascular beds are obtained from the literature except for the peripheral resistance Rp. This has been
calculated according to 1/Rp = 1/Rtot – 1/Rspl/hep – 1/Rren.
Pressure (ΔP, mmHg) Flow (F, L/min) Resistance (R, dyne x s x cm-5 )
Before After 5 min After 1 yr Before After 5 min After 1 yr Before After 5 min After 1 yr
Total vascular 83 83 86 7.0 11.7 7.2 953 590 960
Splanchnic 59 73 76 0.8 5.3 1.8 5900 1101 3377
Hepatic/portal 24 10 10 0.8 5.3 1.8 2400 151 444
Renal 83 83 86 0.232 0.232 0.555 13,453 13,453 7009
Peripheral 1168 1225 1574
Table 3. Conductancies (1/R) of the various vascular beds before, 5 min, and
1-year after TIPS implantation. Conductancies are additive in parallel allowing
calculation of the peripheral conductance as the difference of total vascular
conductance and splanchnic/hepatic plus renal conductancies.
Conductance (1/R x 1000)
Before 5 min after 1 yr after
TIPS
Total vascular 1.05 1.69 1.04
Splanchnic hepatic/portal 0.120 0.8 0.262
Renal 0.074 0.074 0.143
Peripheral 0.856 0.816 0.635
JOURNAL OF HEPATOLOGYaverage number of paracenteses-per-patient was signiﬁcantly
lower in patients allocated to TIPS (1.6 ± 3.5 vs. 7.1 ± 8.8;
p <0.0001). With respect to other complications related to portal
hypertension (gastrointestinal bleeding, SBP and HRS), the overall
rate of these complications was signiﬁcantly lower in the TIPS
group than in the paracentesis group (15% vs. 28%; p = 0.005)
[59].
Survival
With respect to survival, the 6 randomized studies from France
[102], Germany [43], Spain/USA [113], USA/Canada [114], Italy
[115], and Japan [116] show inconsistent results [73]. The lastJournal of Hepatology 2013study published in 2011 has not been included in the numerous
meta-analyses [59,117–120]. Three of the 5 meta-analyses [118–
120] disregarded heterogeneity. One meta-analysis [120] incor-
porated incorrect data from the Italian publication by mixing
up ‘‘patients in study’’ and ‘‘percentages died’’ [121]. Only the
meta-analysis performed by D’Amico et al. [117] eliminated het-
erogeneity by identifying the French study as its source. Actuarial
rates of survival became now different between groups favoring
TIPS (POR 0.74). The meta-analysis of individual patients’ data
by Salerno et al. [59] showed that TIPS patients lived signiﬁcantly
longer than patients treated with paracentesis. TIPS also seems to
improve the estimated transplant free survival in patients with
MELD scores between 10 and 20, suggesting that even patients
with severe disease may beneﬁt from TIPS. In a multivariate anal-
ysis, factors predicting mortality were older age (p = 0.015), high
bilirubin levels (p = 0.022), low sodium concentration (p = 0.03),
and TIPS (HR 0.61, 95% CI 0.41–0.91, p = 0.015).
By considering the 2 relevant meta-analyses [59,117], the
German guidelines recommend TIPS as ﬁrst line treatment in
patients with cirrhosis and refractory ascites [122].Hepatorenal syndrome [HRS]
As shown above, TIPS improves renal function and hemodynamic
variables. Even patients with cirrhosis and parenchymal kidney
disease may beneﬁt from TIPS [123]. Many patients with
HRS type 1, however, suffer from advanced hepatocellularvol. 59 j 1081–1093 1087
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Fig. 7. Conductancies (1/R) of local vascular beds before, 5 min, and 1 year
after TIPS implantation. The renal conductance increases (decreasing resistance)
as a result of a decrease in the peripheral conductance (increased resistance).
Reviewinsufﬁciency with serum bilirubin concentrations exceeding
5 mg/dl, a clear contraindication for TIPS. As summarized
recently [73], a total of 61 patients with HRS receiving a TIPS have
been included in a number of small studies [104,124–126]. In the
largest study, 31 non-transplantable patients (14 type 1 and 17
type 2) were included [124]. Their renal function improved after
TIPS and the 1 and 2-year survival rates were 20% for type 1 and
70% and 45%, respectively, for type 2 HRS. Liver failure was one of
the most frequent causes of death following TIPS. TIPS may also
have a role in maintaining patients who initially respond to vaso-
constrictor treatment [125] and awaiting transplantation [126].
Hepatic hydrothorax
Hepatic hydrothorax is due to direct passage of peritoneal ﬂuid
via diaphragmatic leaks. The treatment modalities including TIPS
have been summarized and discussed recently [73,127,128].
Overall, 198 patients (predominantly Child-Pugh B and C) receiv-
ing a TIPS were included in 6 studies [129–134]. The mean com-
plete and partial (not requiring thoracenteses) response rates
were 65 and 15%, respectively. The average 30-day survival was
around 80%. The 1-year survival, given in 2 studies [131,134],
was 64 and 48%, respectively. Survival was correlated with
response, age <60 to 65 years, and the MELD score [73]. Com-
pared with other treatment options, TIPS seems to provide a high
rate of response and a rather good long-term survival. In addition,
TIPS is the only treatment option which also treats the refractory
ascites, the source of the hepatic hydrothorax.
Vascular abnormalities indicating TIPS
Budd-Chiari syndrome (BCS)
The BCS may present as a fulminant/acute, subacute, or chronic
disease depending on the velocity and extent of the thrombosis
formation [135]. This and accompanying complications, such as
portal vein thrombosis, thrombosis of inferior caval vein, or renal
failure are the relevant parameters determining outcome. In
patients with acute disease, anticoagulation together with sup-
portive treatment (volume, antibiotics, diuretics) is given to
bridge the time until sufﬁcient collaterals have been developed
[136]. In patients with subacute or chronic BCS, the complications
of portal hypertension dominate the clinical picture. Irrespective1088 Journal of Hepatology 2013of the course of the disease, a side-to-side shunt or liver trans-
plantation is an option if medical treatment fails [137,138].
The rationale for a side-to-side shunt is to improve hepatic
blood ﬂow and function by creation of an artiﬁcial outﬂow via
the portal vein bed [138]. In addition, the shunt reduces portal
hypertension and relieves from splanchnic congestion. As dem-
onstrated by numerous case reports and by cohort studies
[139,140], this can be achieved not only by a surgical shunt but
also by TIPS. The latter may have a lower ‘‘operative’’ risk and
is not compromised by the characteristic inferior caval vein
obstruction which is due to the enlarged liver. It is the reason
why portacaval shunting is often impossible or ineffective,
requiring a cavo-atrial shunt in addition [138]. Moreover, liver
transplantation, an option in some of these patients, remains
untouched by the transjugular shunt.
In a minority of patients, one or more hepatic veins are ste-
nosed or occluded over a short segment only. This short segment
Budd-Chiari syndrome may ideally be treated by angioplasty
with or without stenting as described previously [141–143]. This
leads to a reconstruction of the natural vascular bed and blood
ﬂow and has, therefore, priority over the shunt treatment as long
as cirrhosis has not developed.
The major obstacle of TIPS treatment in patients with BCS is
the difﬁculty to catheterize the occluded hepatic vein. This is,
however, overcome by the technique of direct, transcaval punc-
ture of the liver parenchyma with subsequent implantation of a
covered stent [139]. The latter has been shown to improve short
and long-term patency considerably [144,145]. In contrast to
patients receiving a transjugular shunt for variceal bleeding,
where a graded reduction of the portal pressure may be advisable
[23], in BCS patients a larger diameter of the shunt may be rec-
ommended to allow decompression of both the sinusoidal and
splanchnic beds and to facilitate arterial perfusion [139]. During
and after the transjugular shunt intervention, patients should
receive anticoagulation and/or platelet aggregation inhibitors.
Physicians should be aware of the high incidence of heparin
induced thrombosis in patients with BCS (about 30%) [139] and,
therefore, heparin should be given with caution or replaced. In
case of portal or inferior caval thrombosis, local thrombolytic
treatment seems to be safe and effective [139].
With respect to survival, favourable results with a 90% 5-year
and 80% 10-year survival can now be expected, irrespective of
whether the course of the disease was acute or even fulminant
[136,139,140]. With the availability of TIPS, liver transplantation
has become a rare exception.
Sinusoidal obstruction syndrome/veno-occlusive disease (VOD)
The sinusoidal obstruction syndrome is almost always seen in the
setting of bone marrow transplantation. Several case reports
were published showing beneﬁcial effects of TIPS on liver disease
but not on survival [146,147]. The data, however, is very limited
and, therefore, the role of TIPS remains undetermined
[136,148,149].
Portal vein thrombosis
Portal vein thrombosis occurs in up to 28% of patients with cir-
rhosis with a cumulative incidence of 12.8%, 20%, and 38.7% at
1, 5, and 8–10 years of follow-up, respectively, and had little
inﬂuence on prognosis [150,151]. A hypercoagulative state is an
exception [152,153] suggesting that hemodynamic factors play
the dominant role. Warfarin treatment resulted in completevol. 59 j 1081–1093
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resolution of the thrombus in 39%, partial resolution in 43% and
no change in 18% [152]. Anticoagulation using low molecular
weight heparin for 6 months has also been recommended after
exclusion of esophageal or gastric varices [154]. A recent study
investigated the effect of TIPS on portal vein thrombosis in cir-
rhosis [155]. 87% of patients improved with a complete recanali-
sation in 57%. Long-term outcome was excellent with a 24-month
survival of 81%. It should be mentioned that additional anticoag-
ulation during or after the TIPS procedure was not applied. Con-
sidering the positive results, several factors argue in favour of
TIPS: ﬁrst, portal perfusion is already abolished or limited by
thrombosis and TIPS may not exert its known negative effects.
Second, if complications of portal hypertension are present, TIPS
implantation may be beneﬁcial for their treatment. Third, later
use of TIPS in case of its urgent indication may be more difﬁcult
due to aging of the thrombus or extension into intrahepatic
branches. However, the ﬁndings that portal vein thrombosis does
not affect outcome [150,151] argue against any treatment. Ran-
domized studies are required to conﬁrm recent ﬁndings and to
more properly select patients which may beneﬁt from treatment.
TIPS treatment has also been applied to patients with cirrhotic
or non-cirrhotic portal vein thrombosis with cavernomatous
transformation. In patients with a relevant communication
between an intrahepatic portal branch and the extrahepatic col-
laterals, TIPS may be effective in draining the varices and prevent
bleeding. Four studies including 85 patients with portal caverno-
ma successfully implanted a TIPS in 73%, 83%, 35%, and 63%,
respectively [156–159]. Rebleeding was signiﬁcantly reduced in
patients without cirrhosis [158], but not in cirrhosis [159].
Key Points 2
• TIPS improves circulatory dysfunction by redistribution
of local vascular resistances favoring renal perfusion
• TIPS improves survival and reduces portal hypertensive
complications in patients with refractory ascites
• In patients with Budd-Chiary syndrome not responding
rapidly to medical therapy, TIPS is the treatment of
choice. The transplant-free 10-year survival of 80%
reduces the need for liver transplantation to a great
extent 
• Cirrhotic or non-cirrhotic portal vein thrombosis is no
more a contraindication for TIPS. Its effect on mortality
remains to be determined
ConclusionsTechnical advancements in skills and stents have reduced com-
plications and improved patency of TIPS. The major obstacle
remains hepatic encephalopathy, which requires proper selection
of patients and smaller shunts. In patients with acute variceal
bleeding and high risk of early rebleeding, recent studies showed
improved survival recommending early TIPS implantation. With
respect to the prevention of rebleeding (secondary prophylaxis),
TIPS remains the second-line treatment unless new studies with
covered stents demonstrate its superiority over standard medicalJournal of Hepatology 2013therapy. As demonstrated in 2 relevant meta-analyses, TIPS
improves survival in patients with refractory ascites, justifying
its earlier application. It clearly reverses the circulatory dysfunc-
tion which leads to normalization of the renal function. With a
10-year survival rate of 80%, TIPS is the preferred treatment in
patients with Budd-Chiari syndrome who do not respond sufﬁ-
ciently to medical treatment.Conﬂict of interest
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